HIMS Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 34.4%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Eli Lilly & Co.'s return on equity of 104.39%.

Hims & Hers Health, Inc. has a consensus price target of $27.46, signalling upside risk potential of 75.68%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Hims & Hers Health, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Hims & Hers Health, Inc. is more attractive than Eli Lilly & Co..

Hims & Hers Health, Inc. has a beta of 2.431, which suggesting that the stock is 143.147% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 28.90x while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 1.75x versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -121.83%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Moderna, Inc.'s return on equity of -29.19%.

Hims & Hers Health, Inc. has a consensus price target of $27.46, signalling upside risk potential of 75.68%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16.28%. Given that Hims & Hers Health, Inc. has higher upside potential than Moderna, Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Moderna, Inc..

Hims & Hers Health, Inc. has a beta of 2.431, which suggesting that the stock is 143.147% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Moderna, Inc. quarterly revenues of $678M. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Moderna, Inc.'s net income of -$826M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 28.90x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 1.75x versus 9.98x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -9.34%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Pfizer Inc.'s return on equity of 10.84%.

Hims & Hers Health, Inc. has a consensus price target of $27.46, signalling upside risk potential of 75.68%. On the other hand Pfizer Inc. has an analysts' consensus of $28.56 which suggests that it could grow by 7.18%. Given that Hims & Hers Health, Inc. has higher upside potential than Pfizer Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Pfizer Inc..

Hims & Hers Health, Inc. has a beta of 2.431, which suggesting that the stock is 143.147% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.45% to investors and pays a quarterly dividend of $0.43 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 28.90x while Pfizer Inc.'s PE ratio is 19.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 1.75x versus 2.43x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teladoc Health, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -7.9%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Teladoc Health, Inc.'s return on equity of -15.44%.

Hims & Hers Health, Inc. has a consensus price target of $27.46, signalling upside risk potential of 75.68%. On the other hand Teladoc Health, Inc. has an analysts' consensus of $8.93 which suggests that it could grow by 88.44%. Given that Teladoc Health, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Teladoc Health, Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.431, which suggesting that the stock is 143.147% more volatile than S&P 500. In comparison Teladoc Health, Inc. has a beta of 2.119, suggesting its more volatile than the S&P 500 by 111.894%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teladoc Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Teladoc Health, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Teladoc Health, Inc. quarterly revenues of $626.4M. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Teladoc Health, Inc.'s net income of -$49.5M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 28.90x while Teladoc Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 1.75x versus 0.33x for Teladoc Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.